Trump order directs federal agencies to reclassify marijuana from Schedule I to Schedule III, reshaping federal drug policy
- On Dec. 18, President Donald Trump signed an executive order in the Oval Office to reschedule marijuana from Schedule I to Schedule III with `Today, I'm pleased to announce that I will be signing an executive order to reschedule marijuana from a schedule one to a schedule three controlled substance with legitimate medical uses`, Trump said.
- Since 1970, marijuana was classified as Schedule I with no accepted medical use, while President Joe Biden's review and a 2024 proposed rescheduling rule stalled.
- Industry groups say rescheduling could lower tax burdens, ease banking, and expand research access, while premarket trading showed Tilray shares up nearly 5% and SNDL rising 3%.
- The order directs Attorney General Pam Bondi to hasten rescheduling without a timeline, officials stressed it "is not the legalization" and asks aides to work with Congress and HHS on CBD access and Medicare CBD pilot consideration.
- Advocates welcomed the order and said it enables evidence-based discussions, while Nash County Sheriff Keith Stone raised safety concerns and Florida's 2024 ballot initiative failed despite nearly 56% support.
524 Articles
524 Articles
'Mission accomplished': Montana marijuana industry reacts to Trump rescheduling order
Top of mind for industry advocates is prospect of providers writing off their business expenses, which was previously precluded because they were dealing with a federally illegal drug.
Trump's move on marijuana ends often-used argument against access in Nebraska
President Donald Trump signed an executive order Thursday reclassifying marijuana from a Schedule I drug to Schedule III, opening up medical research opportunities and classifying the substance as less dangerous than drugs like heroin and ecstasy.
According to the president, many people have been pleading for the expansion of the use of cannabis, especially those who struggle with illnesses that cause great pain.
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium






































